Sugemalimab
2 clinical trials
1 product
3 abstracts
3 indications
Indication
lung cancerIndication
Extensive-stage Small-cell Lung CancerIndication
Limited-Stage Small Cell Lung CancerAbstract
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,
Abstract
Sugemalimab in locally advanced and advanced Chinese NSCLC: A real-world retrospective study.Org: Department of Medical Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Department of Medical Oncology, Beijing Chaoyang Sanhuan Cancer Hospital, Beijing, Beijing, China, Department of Medical Oncology, Cancer Hospital of HuanXing, ChaoYang District, Beijing, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China,
Clinical trial
Phase I Study of Low-Dose Radiotherapy Plus Chemotherapy and Sugemalimab and Olaparib for First-Line Treatment of SLFN-11 Positive Extensive Stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-06-20
Clinical trial
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential ChemoradiotherapyStatus: Recruiting, Estimated PCD: 2025-12-31
Abstract
A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.Org: Columbia University Medical Center, Memorial Sloan Kettering Cancer Center,